Inhaled Antibiotics Market Analysis | Coherent Market Insights

1
Coherent Market InsightS

• Market Research and Business Consulting
  Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
Inhaled Antibiotics Market Analysis (2020-2027)

• The management of patients with chronic
  respiratory diseases have become a challenge in
  clinical practice. Conditions such as cystic
  fibrosis (CF) and non-CF bronchiectasis require
  extensive treatment strategies to deal with
  multidrug resistant pathogens that include
  Pseudomonas aeruginosa, Methicillin-resistant
  Staphylococcus aureus, Burkholderia species, and
  non-tuberculous Mycobacteria (NTM).
• To overcome these challenges scientists are
  developed a noval drug formulation of
  antimicrobial agent and deliver drugs to the
  pulmonary system by using inhaled, aerosolized or
  nebulized antibiotics.

3

• The important application of inhaling antibiotics
  is to maximize drug delivery to the target site
  of infection i.e. the airways and limit the
  potential for systemic side effects.
• The global inhaled antibiotics market size was
  valued at US 1,094.6 million in 2019 and is
  expected to exhibit a CAGR of 6.3 over the
  forecast period (20202027).

4
Figure 1 Global Inhaled Antibiotics Market Value
(US Mn), by Region, 2020
5
Increasing incidence of respiratory diseases is
expected to drive the market growth over the
forecast period

• Rising incidence of respiratory diseases such as
  asthma, chronic obstructive pulmonary diseases
  (COPD), and bronchitis is expected to drive the
  market growth over the forecast period.
• According to the World Health Organization Report
  May 2020, asthma is the most common chronic
  disease among children worldwide and around 339
  million people were living with asthma in 2016.
  Similarly, according to the same source, over 80
  of asthma-related deaths occur in low-and
  lower-middle income countries.

6
(No Transcript)
7
s

• Moreover, according to the World Health
  organization 2017 report, around 251 million
  cases of chronic obstructive pulmonary diseases
  were found globally in 2016 and around 3.17
  million deaths were caused by chronic obstructive
  pulmonary diseases in 2015. Similarly, according
  to the same source, more than 90 of COPD deaths
  occur in low and middle income countries

8
Figure 2 Global Inhaled Antibiotics Market Share
(), by Product Type, (2020-2027)
9
Increasing new product launches and approvals is
expected to drive the market growth over the
forecast period

• Key players operating in the global market are
  focusing on novel product launches, in order to
  expand their product portfolio and increase their
  presence in the global market.
• For instance, in October 2017, Polyphor, a Swiss
  specialty pharmaceutical company, launched an
  inhaled form of the investigational antibiotic
  murepavadin (POL7080). Murepavadin, a type of
  outer membrane protein targeting antibiotic
  (OMPTA), acts specifically against the bacterial
  strain Pseudomonas aeruginosa, which is a strain
  found in patients with several lung diseases,
  including cystic fibrosis- and non-cystic
  fibrosis-associated bronchiectasis.

10

• In February 2016, Teva Canada Limited, a
  subsidiary of Teva Pharmaceutical Industries
  Ltd., received approval from Health Canada for
  the application of its generic version
  of PrTeva-Tobramycin Inhalation Solution. This
  respiratory antibiotic is indicated for the
  management of cystic fibrosis patients with
  chronic pulmonary Pseudomonas aeruginosa (P.
  aeruginosa) infections.
• Moreover, in April 2016, Raptor Pharmaceutical
  Corp., a biopharmaceutical company, launched its
  QUINSAIR (levofloxacin inhalation solution) in
  Germany and Denmark. It is the first
  fluoroquinolone to be approved as an inhaled
  therapy for a pulmonary disease. QUINSAIR is
  approved in the European Union (EU) and Canada
  for the management of chronic pulmonary
  infections caused due to Pseudomonas aeruginosa
  in adult patients with cystic fibrosis (CF).

11
Global Inhaled Antibiotics Market - Impact of
Coronavirus (Covid-19) Pandemic

• Since the COVID-19 virus outbreak in December
  2019, the disease has spread to almost 100
  countries across the globe with the World Health
  Organization declaring it a public health
  emergency.
• For instance, according to the World Health
  Organization report, as of May 15, 2020, there
  are 4,307,287 individuals affected with
  coronavirus, globally. The global impact of the
  coronavirus disease 2019 (COVID-19) has already
  begun to affect everyone and will significantly
  affect the inhaled antibiotics market in 2020.
  Increasing incidence of COVID-19 can affect the
  global economy by directly affecting production
  and demand for the products, by creating supply
  chain and market disruption, and by its financial
  impact on firms and financial markets.

12
Inhaled Antibiotics Market Restraint

• However, side effects associated with drug
  inhalation and unattainability of single
  effective inhaler device that can treat many
  disease conditions may hinder growth of the
  market.

13
Key Players

• Major players operating in the global inhaled
  antibiotics market include Gilead Sciences,
  Aradigm, Lupin Ltd., Polyphor, Insmed
  Incorporated, Pharmaero, Savara Pharmaceuticals,
  Joincare Pharmaceutical Group, and Pharmaxis Ltd.

14

• Request sample copy here
• Request PDF brochure here
• Request Customization here
• Talk to Analyst
• Buy Now
• Reference
• https//www.coherentmarketinsights.com/market-insi
  ght/inhaled-antibiotics-market-3980

15
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

16
Contact Us   

• Mr. Shah
• Coherent Market Insights Pvt. Ltd.
• Address 1001 4th ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

17
Thank You!

• Kindly follow CMI Social Media Profiles for the
  latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/